ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 688.6 EUR | +2.08% |
|
+0.50% | +30.42% |
| 02/05 | Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK | MT |
| 02/05 | Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1 | RE |
| Sales 2024 * | 42.76B 39.85B 3,565B | Sales 2025 * | 52.13B 48.57B 4,345B | Capitalization | 681B 634B 56,733B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.94B 11.12B 995B | Net income 2025 * | 16.29B 15.18B 1,358B | EV / Sales 2024 * | 16.4 x |
| Net Debt 2024 * | 19.98B 18.62B 1,666B | Net Debt 2025 * | 15.29B 14.24B 1,274B | EV / Sales 2025 * | 13.3 x |
| P/E ratio 2024 * |
56.3
x | P/E ratio 2025 * |
41.2
x | Employees | 43,000 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.79% | Free-Float | 99.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +2.08% | ||
| 1 week | +0.50% | ||
| Current month | -5.48% | ||
| 1 month | -5.48% | ||
| 3 months | +15.63% | ||
| 6 months | +29.44% | ||
| Current year | +30.42% |
1 week
672.00
724.10
1 month
672.00724.20
Current year
529.00736.00
1 year
367.00736.00
3 years
152.30736.00
5 years
94.90736.00
10 years
94.90736.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 712.9 | -1.55% | 0 |
| 30/24/30 | 724.1 | +6.06% | 0 |
| 29/24/29 | 682.7 | -0.86% | 0 |
| 26/24/26 | 688.6 | +2.08% | 15 |
| 25/24/25 | 674.6 | -1.58% | 0 |
End-of-day quote Wiener Boerse, April 26, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
06/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
755.9
USD
Average target price
848.3
USD
Spread / Average Target
+12.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.07% | 556B | |
| -4.35% | 361B | |
| +17.65% | 325B | |
| +3.77% | 285B | |
| +14.68% | 235B | |
| +4.71% | 199B | |
| -12.43% | 189B | |
| -3.79% | 157B | |
| -3.34% | 149B |
- Stock Market
- Equities
- LLY Stock
- LLYC Stock
